세계의 간섬유증 치료제 시장 : 약제 유형별, 유통 채널별 예측(2025-2030년)

The Liver Fibrosis Drugs Market was valued at USD 14.28 billion in 2023, expected to reach USD 15.57 billion in 2024, and is projected to grow at a CAGR of 9.74%, to USD 27.38 billion by 2030.

The scope of the liver fibrosis drugs market encompasses the development, production, and distribution of therapeutic drugs aimed at treating liver fibrosis, a condition characterized by the excessive accumulation of extracellular matrix proteins, leading to scar tissue formation and deteriorating liver function. With advancing medical technology, the necessity for effective liver fibrosis treatments is driven by increasing incidences of liver diseases, such as hepatitis, cirrhosis, and non-alcoholic steatohepatitis (NASH). These therapies are applied across various end-use sectors, including hospitals, clinics, and research institutes, to manage symptoms, slow disease progression, and improve patient outcomes. Key factors influencing market growth include the escalating prevalence of liver diseases due to lifestyle changes, alcohol consumption, and an aging population, alongside increased government and private sector funding for research and development in healthcare. However, challenges such as the high cost of drug development, stringent regulatory hurdles, and limited efficacy of current treatments impede market expansion. These constraints highlight an opportunity for innovation, particularly in developing cost-efficient and effective therapeutic solutions, leveraging advancements in precision medicine and biotechnology. Enhanced collaboration between pharmaceutical companies and research institutions can accelerate the discovery of novel drug targets and delivery systems. Furthermore, the rise in demand for personalized medicine presents potential opportunities for tailored treatment plans, fostering more effective management of liver fibrosis. To capitalize on these opportunities, companies should invest in R&D and strategic partnerships to advance clinical trials and expedite approval processes. The nature of the market, being dynamic and competitive, necessitates continuous innovation to cater to unmet medical needs. Meanwhile, emerging regions offer expansion opportunities, given their growing healthcare infrastructure and patient base. Engaging stakeholders through awareness campaigns and education about liver health can also drive market penetration and acceptance of new products.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Liver Fibrosis Drugs Market

The Liver Fibrosis Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of chronic liver diseases worldwide
  • Favorable reimbursement policies for treatment of liver fibrosis
• Market Restraints
  • Complexity in formulation and development of liver fibrosis drugs
• Market Opportunities
  • Emerging research funding for the development of novel liver fibrosis drugs
  • Improvements in liver imaging techniques and biomarkers for liver fibrosis
• Market Challenges
  • Stringent regulatory frameworks for drug approval of liver fibrosis

Porter's Five Forces: A Strategic Tool for Navigating the Liver Fibrosis Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Liver Fibrosis Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Liver Fibrosis Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Liver Fibrosis Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Liver Fibrosis Drugs Market

A detailed market share analysis in the Liver Fibrosis Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Liver Fibrosis Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Liver Fibrosis Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Liver Fibrosis Drugs Market

A strategic analysis of the Liver Fibrosis Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Liver Fibrosis Drugs Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Arbutus Biopharma, AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Dicerna Pharmaceuticals, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., FibroGen, Inc., Gilead Sciences, Inc., GlaxoSmithKline PLC, Hepion Pharmaceuticals, Inc., Inventiva S.A., LG Life Science Ltd., Madrigal Pharmaceuticals, Inc., Merck & Co., Inc., Mirum Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Pharmaxis Limited, and Sanofi SA.

Market Segmentation & Coverage

This research report categorizes the Liver Fibrosis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Type, market is studied across Antifibrotic Agents, Antioxidant Inflammation Modulators, Antiviral Drugs, and Immune Modulators.
• Based on Distribution Channel, market is studied across Offline Pharmacies and Online Pharmacies. The Offline Pharmacies is further studied across Hospital Pharmacies and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of chronic liver diseases worldwide
    • 5.1.1.2. Favorable reimbursement policies for treatment of liver fibrosis
  • 5.1.2. Restraints
    • 5.1.2.1. Complexity in formulation and development of liver fibrosis drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging research funding for the development of novel liver fibrosis drugs
    • 5.1.3.2. Improvements in liver imaging techniques and biomarkers for liver fibrosis
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory frameworks for drug approval of liver fibrosis
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Type: Growing usage of antifibrotic agents to prevent and reduce the formation of fibrosis
  • 5.2.2. Distribution Channel: Improved access to liver fibrosis drugs due to online pharmacies 24*7 services
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Liver Fibrosis Drugs Market, by Drug Type

• 6.1. Introduction
• 6.2. Antifibrotic Agents
• 6.3. Antioxidant Inflammation Modulators
• 6.4. Antiviral Drugs
• 6.5. Immune Modulators

7. Liver Fibrosis Drugs Market, by Distribution Channel

• 7.1. Introduction
• 7.2. Offline Pharmacies
  • 7.2.1. Hospital Pharmacies
  • 7.2.2. Retail Pharmacies
• 7.3. Online Pharmacies

8. Americas Liver Fibrosis Drugs Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Liver Fibrosis Drugs Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Liver Fibrosis Drugs Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
  • 11.3.1. Survodutide Phase II Trial Shows 83% of Adults Treated Achieved Groundbreaking Results in Liver Disease due to MASH, with Significant Improvements in Fibrosis
  • 11.3.2. Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare Cholestatic Liver Disease
  • 11.3.3. Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Amgen Inc.
• 2. Arbutus Biopharma
• 3. AstraZeneca PLC
• 4. Bayer AG
• 5. Boehringer Ingelheim International GmbH
• 6. Bristol-Myers Squibb Company
• 7. Dicerna Pharmaceuticals, Inc.
• 8. Eli Lilly and Company
• 9. F. Hoffmann-La Roche Ltd.
• 10. FibroGen, Inc.
• 11. Gilead Sciences, Inc.
• 12. GlaxoSmithKline PLC
• 13. Hepion Pharmaceuticals, Inc.
• 14. Inventiva S.A.
• 15. LG Life Science Ltd.
• 16. Madrigal Pharmaceuticals, Inc.
• 17. Merck & Co., Inc.
• 18. Mirum Pharmaceuticals, Inc.
• 19. Novartis AG
• 20. Pfizer Inc.
• 21. Pharmaxis Limited
• 22. Sanofi SA